Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3020% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker Full-Year Guidance by Quarter
Full-Year Guidance — Adjusted Diluted EPS High End ($) ($)
Stryker Full-Year Guidance: $14.90 in Q3 2026, up 9.6% from a year earlier.
Latest, Q3 2026
14.90
Period ended Sep 30, 2026
Change on a year earlier
+9.6%
13.60 in Q3 2025
History
34 quarters
Since Q4 2016
Sources
34
Documents cited below
Where the Q3 2026 figure comes from
“adjusted net earnings per diluted share (2) to be in the range of $14.80 to $14.90”
Reported in Stryker Form 8-K Outlook Section.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Stryker Full-Year Guidance ($), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/core-guid-eps-high
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.